Literature DB >> 370979

Binding of cis- and trans-dichlorodiammineplatinum(II) to DNA: evidence for unwinding and shortening of the double helix.

G L Cohen, W R Bauer, J K Barton, S J Lippard.   

Abstract

The antitumor drug cis-dichlorodiammineplatinum(II) (cis-DDP) and the inactive trans isomer bind and produce cooperative changes in closed and nicked circular duplex DNA's. Covalent binding of both platinum complexes to the closed circular DNA alters the degree of supercoiling, presumably by disrupting and unwinding the double helix. Electron micrographs show the platinated DNA's to be shortened by up to 50 percent of their original length. At similar ratios of bound platinum per nucleotide, the electrophoretic mobilities of the DNA's in gels containing the dye ethidium bromide are the same for both isomers. The only detectable difference in the binding of the two platinum isomers is an increase in the electrophoretic mobility in nondye gels of closed circular DNA having small amounts of bound cis-DDP that is not apparent for the trans complex.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 370979     DOI: 10.1126/science.370979

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  39 in total

1.  Noncovalent DNA binding drives DNA alkylation by leinamycin: evidence that the Z,E-5-(thiazol-4-yl)-penta-2,4-dienone moiety of the natural product serves as an atypical DNA intercalator.

Authors:  Mostafa I Fekry; Jozsef Szekely; Sanjay Dutta; Leonid Breydo; Hong Zang; Kent S Gates
Journal:  J Am Chem Soc       Date:  2011-10-18       Impact factor: 15.419

2.  Understanding the effect of carbonate ion on cisplatin binding to DNA.

Authors:  Ryan C Todd; Katherine S Lovejoy; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2007-04-28       Impact factor: 15.419

3.  Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand.

Authors:  Yousef Najajreh; Jana Kasparkova; Victoria Marini; Dan Gibson; Viktor Brabec
Journal:  J Biol Inorg Chem       Date:  2005-11-08       Impact factor: 3.358

4.  Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes.

Authors:  Leonor Côrte-Real; Filipa Mendes; Joana Coimbra; Tânia S Morais; Ana Isabel Tomaz; Andreia Valente; M Helena Garcia; Isabel Santos; Manuel Bicho; Fernanda Marques
Journal:  J Biol Inorg Chem       Date:  2014-02-23       Impact factor: 3.358

5.  X-ray structure and mechanism of RNA polymerase II stalled at an antineoplastic monofunctional platinum-DNA adduct.

Authors:  Dong Wang; Guangyu Zhu; Xuhui Huang; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-06       Impact factor: 11.205

Review 6.  Nanocarriers for delivery of platinum anticancer drugs.

Authors:  Hardeep S Oberoi; Natalia V Nukolova; Alexander V Kabanov; Tatiana K Bronich
Journal:  Adv Drug Deliv Rev       Date:  2013-10-08       Impact factor: 15.470

7.  Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.

Authors:  M C Poirier; S J Lippard; L A Zwelling; H M Ushay; D Kerrigan; C C Thill; R M Santella; D Grunberger; S H Yuspa
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

8.  Binding of cis- and trans-dichlorodiammineplatinum(II) to the nucleosome core.

Authors:  S J Lippard; J D Hoeschele
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

9.  Reactions of the UVRABC excision nuclease with DNA damaged by diamminedichloroplatinum(II).

Authors:  D J Beck; S Popoff; A Sancar; W D Rupp
Journal:  Nucleic Acids Res       Date:  1985-10-25       Impact factor: 16.971

10.  The tumor-inhibiting effect of isomeric dichloro(diphenylethylenediamine)platinum(II) complexes.

Authors:  B Wappes; M Jennerwein; E von Angerer; J Engel; H Schönenberger; H Brunner; M Schmidt; M Berger; D Schmähl; S Seeber
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.